Global Drugs For Benign Prostatic hypertrophy Market Share 2024, Forecast To 2033
10 Jan, 2024
The market for drugs addressing benign prostatic hypertrophy (BPH) has experienced strong growth, increasing from $4.02 billion in 2023 to $4.31 billion in 2024, with a CAGR of 7.1%. Contributing factors include an aging population, increased awareness, advancements in drug therapies, and improved healthcare access. The market is expected to see continued strong growth, reaching $5.45 billion in 2028, with a CAGR of 6.0%. Key drivers include expansion in emerging markets, new drug developments, increased awareness and education, and regulatory approvals. Noteworthy trends include the adoption of minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, and advancements in telemedicine and digital health, as well as ongoing research and development.
Global Drugs For Benign Prostatic hypertrophy Market Key Driver
The increasing elderly male population worldwide propels the growth of the market for drugs targeting Benign Prostatic Hypertrophy (BPH). This condition is prevalent among men aged 50 and above. The World Health Organization estimates that by 2030, one in six individuals globally will be 60 or older, reaching 2.1 billion elderly people by 2050. The National Institute of Health indicates that BPH affects 50% of men aged 51-60 and up to 90% of men over 80.
Get A Free Sample Of The Global Drugs For Benign Prostatic hypertrophy Market ReportGlobal Drugs For Benign Prostatic hypertrophy Market Segments
The drugs for benign prostatic hypertrophy market covered in this report is segmented –
1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
By Geography: The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the drugs for benign prostatic hypertrophy market in 2023. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Drugs For Benign Prostatic hypertrophy Industry Players
Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International plc, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.
Get The Full Global Drugs For Benign Prostatic hypertrophy Market Report
Drugs For Benign Prostatic hypertrophy Market Overview
The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibers in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50.
Drugs For Benign Prostatic hypertrophy Global Market Report 2023 provides data on the global drugs for benign prostatic hypertrophy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The drugs for benign prostatic hypertrophy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.